These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8528762)

  • 21. Superantigen Recognition and Interactions: Functions, Mechanisms and Applications.
    Deacy AM; Gan SK; Derrick JP
    Front Immunol; 2021; 12():731845. PubMed ID: 34616400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen.
    Jardetzky TS; Brown JH; Gorga JC; Stern LJ; Urban RG; Chi YI; Stauffacher C; Strominger JL; Wiley DC
    Nature; 1994 Apr; 368(6473):711-8. PubMed ID: 8152483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural dichotomy of staphylococcal enterotoxin C superantigens leading to MHC class II-independent activation of T lymphocytes.
    Lamphear JG; Bohach GA; Rich RR
    J Immunol; 1998 Mar; 160(5):2107-14. PubMed ID: 9498747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Superantigens as immunomodulators: recent structural insights.
    Papageorgiou AC; Acharya KR
    Structure; 1997 Aug; 5(8):991-6. PubMed ID: 9309216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple binding sites for bacterial superantigens on soluble class II MHC molecules.
    Kozono H; Parker D; White J; Marrack P; Kappler J
    Immunity; 1995 Aug; 3(2):187-96. PubMed ID: 7648392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The structural basis of T cell activation by superantigens.
    Li H; Llera A; Malchiodi EL; Mariuzza RA
    Annu Rev Immunol; 1999; 17():435-66. PubMed ID: 10358765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Staphylococcal enterotoxin H displays unique MHC class II-binding properties.
    Nilsson H; Björk P; Dohlsten M; Antonsson P
    J Immunol; 1999 Dec; 163(12):6686-93. PubMed ID: 10586065
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bacterial and retroviral superantigens share a common binding region on class II MHC antigens.
    Torres BA; Griggs ND; Johnson HM
    Nature; 1993 Jul; 364(6433):152-4. PubMed ID: 8391645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
    Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
    Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modeling of receptor mimics that inhibit superantigen pathogenesis.
    Möllhoff M; Zanden HB; Shiflett PR; Gupta G
    J Mol Recognit; 2005; 18(1):73-83. PubMed ID: 15459942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Major histocompatibility complex class II-associated peptides determine the binding of the superantigen toxic shock syndrome toxin-1.
    von Bonin A; Ehrlich S; Malcherek G; Fleischer B
    Eur J Immunol; 1995 Oct; 25(10):2894-8. PubMed ID: 7589089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two common structural motifs for TCR recognition by staphylococcal enterotoxins.
    Rödström KEJ; Regenthal P; Bahl C; Ford A; Baker D; Lindkvist-Petersson K
    Sci Rep; 2016 May; 6():25796. PubMed ID: 27180909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules.
    Ulrich RG; Bavari S; Olson MA
    Nat Struct Biol; 1995 Jul; 2(7):554-60. PubMed ID: 7664123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity.
    Vath GM; Earhart CA; Monie DD; Iandolo JJ; Schlievert PM; Ohlendorf DH
    Biochemistry; 1999 Aug; 38(32):10239-46. PubMed ID: 10441117
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of engineered vaccines effective against structurally related bacterial superantigens.
    Ulrich RG; Olson MA; Bavari S
    Vaccine; 1998 Nov; 16(19):1857-64. PubMed ID: 9795392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of binding domains on the superantigen, toxic shock syndrome-1, for class II MHC molecules.
    Soos JM; Russell JK; Jarpe MA; Pontzer CH; Johnson HM
    Biochem Biophys Res Commun; 1993 Mar; 191(3):1211-7. PubMed ID: 8466498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interactions between staphylococcal superantigens and MHC class II molecules.
    Labrecque N; Thibodeau J; Sékaly RP
    Semin Immunol; 1993 Feb; 5(1):23-32. PubMed ID: 8467091
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Defining a novel domain of staphylococcal toxic shock syndrome toxin-1 critical for major histocompatibility complex class II binding, superantigenic activity, and lethality.
    Kum WW; Laupland KB; Chow AW
    Can J Microbiol; 2000 Feb; 46(2):171-9. PubMed ID: 10721486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Superantigen vaccines: a comparative study of genetically attenuated receptor-binding mutants of staphylococcal enterotoxin A.
    Bavari S; Dyas B; Ulrich RG
    J Infect Dis; 1996 Aug; 174(2):338-45. PubMed ID: 8699064
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superantigens of gram-positive bacteria: structure-function analyses and their implications for biological activity.
    Kotb M
    Curr Opin Microbiol; 1998 Feb; 1(1):56-65. PubMed ID: 10066470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.